Clinical response rates of COXEN-matched vs. unmatched patient groups in the TCGA cohort after the primary platinum-based chemotherapy.

aAlmost all patients were treated with paclitaxel in the first-line chemotherapy, so the matched patients were predicted to have the highest survival benefit from the drug (of the three) and the unmatched patients were predicted to have the highest survival benefit from the other two drugs.